|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Research and Development,
Héma-Québec, Québec, Canada; and the Department of
Biochemistry and Microbiology, Laval University, Québec, Canada.
The prophylaxis of the hemolytic disease of the newborn requires
significant amounts of plasma-derived polyclonal human anti-D. Because
of procurement problems, there is a growing interest in replacing
plasma-derived anti-D by in vitro-produced human monoclonal anti-D.
Hundreds of monoclonal anti-D have been prepared, but the selection of
the most potent for in vivo use is difficult because it cannot be
predicted by in vitro characterization. This study evaluated the
possibility of using nonobese diabetic/severe combined immunodeficient
(NOD-scid) mice for the in vivo evaluation of human monoclonal anti-D.
Human red blood cells (RBCs) were found to circulate normally in the
blood of NOD-scid mice previously injected with a physiologic amount of
human immunoglobulin G (10 mg). The addition of a small amount of
anti-D (1 to 5 µg) resulted in the clearance of Rh D+
RBCs within 4 hours. The comparative testing of 8 monoclonal anti-Ds
showed a wide range of potency (15% to 87%) relative to plasma-derived polyclonal anti-D. There was no strong correlation between the in vivo potency index and the immunoglobulin G isotype, affinity, or fine specificity of the antibodies. These results show the
usefulness of NOD-scid mice for the initial in vivo screening of human
monoclonal anti-D before testing the most active antibodies in clinical
trials done in human volunteers.
(Blood. 2002;99:1267-1272) Human monoclonal antibodies of various
specificities can now be prepared by using cellular or molecular
technologies. Several of these antibodies could have interesting
therapeutic applications, such as human monoclonal anti-D that could be
used to replace plasma-derived polyclonal antibodies for the prevention
of the hemolytic disease of the newborn.1 Contrary to
plasma-derived anti-D preparations that rely on the availability of
immunized donors, monoclonal anti-D prepared by culture of immortalized cell lines give access to an unlimited supply of standardized preparations. However, as is the case for other antibody specificities, the selection of the most appropriate monoclonal anti-D for therapeutic use represents a significant challenge.
The mechanism by which anti-Ds suppress Rh D immunization is still
unclear. Some of the proposed mechanisms rely on the interaction between the Fc portion of anti-D and different Fc Because of obvious ethical problems in studying Rh D+ RBC
destruction in Rh D In the past 10 years, the isolation of immunodeficient mouse strains
has opened new possibilities for the early in vivo testing of human
proteins and cells. The nonobese diabetic/severe combined immunodeficient (NOD-scid) mice exhibit a combination of immunologic defects, including a lack of functional lymphoid cells, no serum immunoglobulin, low natural killer cell activity, and lack of hemolytic
complement activity. These defects make them particularly good
recipients for xenogenic cells and tissues.11 For example, NOD-scid mice have been used to study the human hematopoietic progenitor development,12-14 HIV
pathogenesis,15-17 and human leukemic cell biology and
treatment.18,19 We selected these mice for this study
because it has been shown that human RBCs could circulate for several
days in the peripheral blood of NOD-scid mice but not in other
immunodeficient strains of mice.20
In this work, we have used NOD-scid mice to compare the ability of
several human monoclonal anti-Ds to mediate Rh D+ RBC
clearance in vivo. The use of NOD-scid mice to study the in vivo
clearance of human RBCs depends on 3 parameters. The first parameter is
the ability to detect human RBCs in the peripheral blood of NOD-scid
mice for a sufficient period of time, and the second parameter is the
ability of the mouse cells to phagocytose RBCs coated with human
antibodies. Finally, the antibody content of the mouse serum should
mimic as closely as possible the situation in humans. Indeed, it has
been observed many years ago that the rate of IgG catabolism in humans
is proportional to the serum IgG concentration.21,22 Our
previous study with immunodeficient mice also showed the strong
correlation between antibody concentration and catabolism
rate.23 Because NOD-scid mice do not have immunoglobulins in their serum, all animals used in this study were injected with human
IgGs to reconstitute a serum immunoglobulin level comparable to normal.
The results obtained showed the suitability of NOD-scid mice for
comparing the ability of anti-D to mediate RBC clearance and indicated
that the relative in vivo potency of the various monoclonal anti-Ds is
not directly related to the antibody IgG subclass, agglutination titer,
and fine specificity.
Mice
Antibodies and F(ab')2 fragments
Serologic tests The agglutination titer of the anti-Ds used in this study was determined by using the indirect agglutination assay.26 Briefly, the anti-D was diluted serially in saline containing 1% bovine serum albumin (100 µL) and was added to 50 µL of a 3% Rh D+ RBC suspension. After incubation (45 minutes at 37°C), the RBCs were washed with saline, and the antihuman globulin reagent (100 µL; Dominion Biological Limited, Nova Scotia, Canada) was added. The tubes were centrifuged for 15 seconds at 700 RPM (Automatic Centrifuge, Dade, Miami, FL). The agglutination titer was defined as the reciprocal of the last dilution giving macroscopic agglutinates (1+ reaction). A commercial preparation of polyclonal anti-D was used as a reference.RBC labeling and conservation RBCs were obtained from volunteer donors in acid citrate dextrose Vacutainer tubes (Becton Dickinson, Ontario, Canada). Because we did not observe differences in RBC survival in NOD-scid mice by using RBCs of different ABO blood groups, the donors were not selected according to their ABO blood group. The RBCs were labeled with chromium-51 (51Cr) by using standard techniques.27 Briefly, RBCs were washed in citrate-dextrose solution (110 mM sodium citrate, 10 mM dextrose, 1 mM sodium phosphate, pH 6.8), and 150 µL packed RBCs were mixed with 11.1 MBq (300 µCi) 51Cr (Amersham Pharmacia Biotech, Quebec, Canada) and incubated at room temperature for 1 hour. The RBCs were then washed twice with saline to remove unincorporated 51Cr. Finally, RBCs were suspended in saline at a final 40% concentration for injection into the animals.Anti-D-mediated RBC clearance in vivo To determine the antibody-mediated RBC clearance, groups of 3 animals were first injected intraperitoneally with a volume of 250 µL containing 10 mg human IgG (IVIg 5%; Bayer, Ontario, Canada) and 5 µg of the antibodies to be tested, unless otherwise indicated. After 18 to 24 hours, the animals received 100 µL of the radiolabeled RBC suspension by injection into the tail vein. Blood was collected by retroorbital bleeding, starting 15 minutes after the intravenous injection and at a maximum of 3 different time points thereafter. A volume of 150 µL was collected in microtubes already containing a small amount of saponin to lyse RBCs, and aliquots of 100 µL were counted in a Gamma Counter to determine the amount of radiolabeled RBCs in the peripheral blood of the animals.
Human RBC survival in NOD-scid mice To reconstitute a serum immunoglobulin level comparable to normal animals, all NOD-scid mice used in this study were injected with 10 mg human IgGs (about 4 mg/mL IgG with a blood volume of 2 to 3 mL).28 Human intravenous IgGs was prepared from pools of plasma obtained from thousands of donors and, thus, contained immunoglobulins with a very wide range of specificities. We first determined whether these human IgGs could by themselves promote clearance of human RBCs in NOD-scid mice, because this would interfere with the subsequent evaluation of the biologic activity of anti-D. The survival of human RBCs in NOD-scid mice in the presence or absence of 10 mg human IgGs was evaluated in groups of animals injected (intraperitoneally) or not with 10 mg human IgGs. It is known that the IgG distribution from the peritoneal cavity to the vascular compartment reaches equilibrium 8 hours after intraperitoneal injection.23 However, for logistical reasons, RBC survival was determined 18 to 24 hours after human IgG injection. RBCs were injected into the tail vein of the animals. In initial experiments, a volume of 100 µL containing 5 µL packed 51Cr-labeled Rh D+ RBCs was injected into each animal. This volume of injected RBCs was similar to the volume used in clinical trials of anti-D in humans,29 taking into account the difference in blood volume between the 2 species. However, we found that the proportion of injected 51Cr-labeled RBCs that was present in the NOD-scid mouse circulation was low (data not shown), suggesting a nonspecific clearance mechanism. To overcome this problem, the labeled Rh D+ RBCs (5 µL) were mixed with a larger volume (35 µL) of unlabeled Rh D RBCs before injection. This
approach resulted in an increase in the proportion of injected
51Cr-labeled RBCs found in the animal circulation (80% on
average) and in more consistent results between animals from the same
experimental group (data not shown). After RBC injection, blood samples
were collected at various intervals, starting at 15 minutes. This
sample represented the starting point (100% survival). Samples were
also taken 90 and 240 minutes after the initial bleeding. The results obtained are shown in Figure 1. A rapid
decrease in circulating 51Cr-labeled RBCs was observed
during the first hour after injection. The rate of clearance decreased
slowly thereafter, and about 50% of the injected RBCs were still in
the circulation 4 hours after the injection. The small reduction in RBC
survival between 1 and 4 hours after injection (about 15%) could be
due in part to the volume of collected blood (150 µL) relative to the
total blood volume of the mice (about 3 mL). This could result in a
reduction of the hematocrit at the late time points and an apparent
decrease in RBC survival. The results in Figure 1 also showed that the amount of 51Cr-labeled RBCs in NOD-scid mouse circulation
was similar over a 4-hour period in animals injected or not with human
IgGs, indicating that human IgGs do not interfere with human RBC
survival in NOD-scid mice.
Antibody-mediated Rh D+ RBC clearance in NOD-scid mice The effect of polyclonal and monoclonal anti-Ds on RBC clearance was tested in the above system. A dose of 5 µg of a plasma-derived polyclonal anti-D preparation was used, which was estimated to be almost in excess considering the low volume of 51Cr-labeled Rh D+ RBCs injected (5 µL). Groups of 3 NOD-scid mice were thus injected with 10 mg of human IgGs containing or not 5 µg of polyclonal anti-D, 16 to 18 hours before the intravenous injection of RBCs. The results obtained are shown in Figure 2. In animals injected with human IgGs only, about 40% to 50% of the injected RBCs were still in the peripheral blood of NOD-scid mice 4 hours after injection, whereas less than 5% of the injected Rh D+ RBCs were detected at that time point in animals treated with human IgGs and polyclonal anti-D. These results indicated that antibody-mediated human RBC clearance occurred in NOD-scid mice. Anti-D-mediated RBC clearance was highly reproducible in different experiments. Indeed, in a series of 10 experiments done over a 6-month period, the mean RBC survivals at 0.5, 2.0, and 4.0 hours were, respectively, 35% ± 9%, 11% ± 3%, and 5% ± 2%.
In the same experiment, we also determined if the antibody-mediated RBC clearance was Fc-dependent. This determination was done by using F(ab')2 fragments of polyclonal anti-D prepared by pepsin digestion. The results obtained (Figure 2) showed that RBC survival was similar in animals injected with human IgGs only or with human IgGs containing F(ab')2 fragments of polyclonal anti-D, indicating that only whole IgG molecules were able to mediate RBC clearance. To rule out the possibility that this result could be due to a shorter half-life of F(ab')2 fragments in NOD-scid mice, we first titrated the anti-D present in the mouse serum 18 hours after injection, using enzyme-treated RBCs to allow direct agglutination by F(ab')2 fragments and whole anti-D. Results obtained showed that anti-D activity could be detected in the serum of mice injected with F(ab')2 fragments (titer of 32) and with whole anti-D (titer of 512). This difference in titer was similar to the one measured in the 2 antibody preparations used to inject the animals. The involvement of Fc regions was also assessed by injecting NOD-scid mice with normal Rh D+ RBCs previously sensitized in vitro with whole anti-D or F(ab')2 fragments. The results obtained (data not shown) were similar to the ones shown in Figure 2 (injection of anti-D 18 hours before RBCs). Altogether, these observations indicated that the anti-D-mediated RBC clearance was an Fc-dependent process in NOD-scid mice. Monoclonal anti-D-mediated RBC clearance Eight different monoclonal anti-Ds (5 IgG1 and 3 IgG3) were tested in NOD-scid mice for their comparative ability to mediate Rh D+ RBC clearance. These anti-Ds have different epitope specificities and exhibit very different potency as tested by RBC agglutination assays done with similar IgG concentrations (Table 1). These monoclonal anti-Ds were tested individually for RBC clearance in groups of 3 NOD-scid mice at a dose of 5 µg/mouse, as described above for the polyclonal anti-D preparation. The results showed that these anti-Ds have a variable capacity to mediate RBC clearance in vivo (Figure 3) and that no monoclonal was as potent as the polyclonal anti-D preparation. We calculated the relative potency of each monoclonal anti-D by using the data obtained at 4 hours and the clearance observed with the polyclonal anti-D preparation as the 100% reference (Table 1). The relative RBC clearance ranged from 87% (46E7) to 15% (19A5). Three of the monoclonal anti-D tested gave relative RBC clearance higher than 80% (46E7, 26C1, and 25F5). The 26C1 (IgG3) and 25F5 (IgG1) anti-Ds gave agglutination titers of 256, which are in the same range as the one obtained with the polyclonal anti-D preparation (512; see Table 1). However, 46E7 has a significantly lower agglutination titer (32; Table 1), which indicates that there is no direct relationship between the ability to agglutinate RBCs in vitro and the ability to mediate RBC clearance in vivo. Indeed, 46E7 has an agglutination titer similar to that of 19A5, the latter being the less-efficient anti-D for mediating RBC clearance in vivo. The absence of relationship between the agglutination titer and the ability to mediate RBC clearance is also illustrated by the 13E10 and 13D2 anti-Ds, which are both comparable in vivo (50% versus 42%) and having significantly different agglutination titers (32 versus 256). Furthermore, comparison of the relative clearance potencies and the recognized D epitopes did not permit us to derive a significant correlation between these 2 characteristics
To determine whether the antibody concentration used was limiting the
extent of RBC clearance, we performed dose-response analyses by using
26C1 and 19A5. The results obtained with 26C1 (Figure
4A and Table 1) showed that the RBC
clearance increased with the dose of 26C1 used. Indeed a dose of 10 µg 26C1 resulted in a RBC clearance comparable to that obtained with
5 µg of polyclonal anti-D (relative RBC clearance of 96%). In the
case of 19A5 (Figure 4B and Table 1), the relative RBC clearance was
very low at a dose of 5 µg (15%). The use of larger amounts of 19A5
permitted to some extent to increase the RBC clearance to about 50%
but not to the level observed with the polyclonal and some other
monoclonal anti-D. Furthermore, the relative RBC clearance observed
with 10 µg 19A5 did not increase with 20 µg, indicating that
factors other than anti-D concentration are involved in RBC clearance in vivo.
Synergistic functional effects have been reported for anti-D in in vitro tests such as antibody-dependent cellular cytotoxicity (ADCC) and monocyte chemiluminescence in which blends containing both IgG1 and IgG3 anti-Ds appeared to be the most active, as did blends containing antibodies recognizing 2 distinct D epitopes.10 We thus tested in NOD-scid mice a blend of monoclonal anti-Ds containing 2 IgG1 (25F5 and 46E7) and one IgG3 (26C1). These anti-Ds recognized 2 different epitopes on the Rh D antigen (epitope 6/7 for 25F5 and 26C1 and epitope 2 for 46E7; Table 1). The blend containing an equal proportion of each monoclonal anti-D was tested at doses of 5 and 10 µg and was compared with a dose of 5 µg polyclonal anti-D. The results obtained (Figure 4C) indicated that the blend did not show synergistic effects at 5 µg and 10 µg and remained less potent than the polyclonal anti-D preparation.
Hundreds of different human monoclonal anti-Ds are now available, but very few of them exhibit a biologic activity comparable to polyclonal anti-D preparations in clinical trials.2 In this work, we have tested the hypothesis of using NOD-scid mice for the in vivo testing of human anti-D. The results obtained showed that NOD-scid mice can be used to evaluate the relative biologic activity of different human anti-Ds in an in vivo environment. This conclusion is derived from experiments in which we observed that the reduction in the amount of human RBCs circulating in the blood of NOD-scid mice was related to the nature and amount of the injected anti-D, thus allowing comparison of the potency of each monoclonal with the one of the plasma-derived polyclonal preparations currently used in humans for the prophylaxis of the hemolytic disease of the newborn. This mouse assay has several characteristics that make it suitable for
extensive in vivo testing of human monoclonal anti-D. To shorten the
time necessary for the in vivo assay, we used a 4-hour post-RBC
injection to determine RBC clearance. Very small volumes of human RBCs
are injected in NOD-scid mice, and we initially observed nonspecific
clearance of human RBCs. This problem was resolved by diluting the
labeled Rh D+ RBCs in a large excess of unlabeled Rh
D RBC clearance assays using a polyclonal anti-D preparation in NOD-scid
mice showed that a dose of 5 µg resulted in the almost complete
clearance of 5µL of Rh D+ RBCs from NOD-scid mouse
circulation within 4 hours (1 µg was less efficient; data not shown).
When considering that 20 to 25 µg is the amount of polyclonal anti-D
required to prevent immunization against 1 mL Rh D+ RBCs in
humans,2,9 it appears that the amount of anti-D required
to clear human RBCs is much higher in NOD-scid mice. The Fc The in vivo analysis of 8 monoclonal anti-Ds tested revealed a wide range of RBC clearance potency when used at similar doses in NOD-scid mice (15% to 87% of polyclonal control). Thus, the NOD-scid mouse assay permits a good discrimination between weak and more active monoclonal anti-Ds. Also we could observe a dosage effect with 26C1 and 19A5, suggesting that the anti-D could also be classified according to their specific activity if additional dose-response experiments were performed. No single monoclonal anti-D could equal the clearance activity of polyclonal anti-D. This result was not totally unexpected, as none of the tested monoclonal anti-D was as potent as the polyclonal anti-D in standard agglutination assays. Two of the 3 most active monoclonal anti-D (26C1, 46E7, and 25F5) were among the group of 4 monoclonal anti-Ds that were the best agglutinators, suggesting a relationship between these 2 parameters. However, the link was not absolute because 46E7 was highly active in vivo and was a poor agglutinator in vitro, whereas the opposite results were obtained with 21H9. Also, no clear relationship could be established between the in vivo results and the IgG subclass or the recognized Rh D epitopes. Altogether these results further emphasize the limitations of in vitro tests for the prediction of in vivo efficacy of anti-D as previously suggested in other studies.9,10 We could not detect a synergy between 26C1, 25F5, and 46E7 when injected as a blend. However, the result may be caused by the experimental design and the fact that the 3 individual anti-Ds were at least 80% as active as the polyclonal preparation. The putative synergy would certainly be more easily detected by using a lower dose of each monoclonal anti-D selected in a range in which the clearance rate would be expected to be proportional to the injected amount (eg, 0.5 µg) as suggested by the dose-response effect observed with 26C1. Concerning the effect of blending, it should be pointed out that our results are in agreement with 2 previous studies done in humans33 and in chimpanzees34 in which no synergy between 2 anti-D was observed. The mechanism by which anti-Ds suppress Rh D immunization is still unclear and may be explained either by efficient RBC clearance or inhibition of B-lymphocyte functions.2 Nevertheless, the selection of monoclonal anti-Ds able to efficiently prevent Rh D immunization should be based on 2 parameters that are the ability of the antibody to bind significantly to Rh D+ RBCs in vivo and the ability of the bound monoclonal to lead to efficient recognition of the opsonized RBCs by the immune cells. The NOD-scid mouse assay described in this work permits us to assess these 2 criteria in the context of phagocytosis, but this assay will obviously not replace the need for clinical trials. However, the use of an in vivo environment to evaluate the ability of anti-D to mediate RBC clearance may reflect more accurately the intrinsic biologic activity of these antibodies when compared with results of in vitro tests because the in vivo environment provided by an animal model is clearly more physiologically relevant than the simple in vitro interaction of antibodies with their antigens. Thus, although not perfect, the NOD-scid mouse assay described here could be very useful to select the best combination and dose of monoclonal anti-D to reproduce the effect of plasma-derived polyclonal preparations before conducting clinical trials in humans.
We thank Ms Huguette Collin for performing the agglutination assays and Dr Patricia Tippett for the determination of the D epitopes recognized by the monoclonal anti-Ds.
Submitted April 20, 2001; accepted October 4, 2001.
Supported by research funding from the Bayer/Canadian Blood Services/ Héma-Québec Partnership Fund (R.B. and R.L.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Renée Bazin, Héma-Québec, R&D Department, 2535 Boul Laurier, Sainte-Foy (Que), Canada, G1V 4M3; e-mail: rbazin{at}hema-quebec.qc.ca.
1. Kumpel BM. Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn. Transfus Clin Biol. 1997;4:351-356[CrossRef][Medline] [Order article via Infotrieve].
2.
Kumpel B, Elson C.
Mechanism of anti-D-mediated immune suppression
3.
Karlsson MC, Wernersson S, Diaz de Stahl T, Gustavsson S, Heyman B.
Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice.
Proc Natl Acad Sci U S A.
1999;96:2244-2249 4. Halma C, Daha MR, van Es LA. In vivo clearance by the mononuclear phagocyte system in humans: an overview of methods and their interpretation. Clin Exp Immunol. 1992;89:1-7[Medline] [Order article via Infotrieve]. 5. Urbaniak SJ. ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies, I: investigation of in vitro culture variables. Br J Haematol. 1979;42:303-314[Medline] [Order article via Infotrieve]. 6. Kumpel BM, Leader KA, Merry AH, et al. Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis. Eur J Immunol. 1989;19:2283-2288[Medline] [Order article via Infotrieve]. 7. Wiener E, Jolliffe VM, Scott HC, et al. Differences between the activities of human monoclonal IgG1 and IgG3 anti-D antibodies of the Rh blood group system in their abilities to mediate effector functions of monocytes. Immunology. 1988;65:159-163[Medline] [Order article via Infotrieve]. 8. Hadley AG, Kumpel BM, Merry AH. The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies. Clin Lab Haematol. 1988;10:377-384[Medline] [Order article via Infotrieve]. 9. Fletcher A, Thomson A. The introduction of human monoclonal anti-D for therapeutic use. Transfus Med Rev. 1995;IX:314-326[CrossRef]. 10. Armstrong-Fisher SS, Carter MC, Downing I, et al. Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function. Transfusion. 1999;39:1005-1012[CrossRef][Medline] [Order article via Infotrieve]. 11. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191[Abstract].
12.
Hogan CJ, Shpall EJ, McNulty O, et al.
Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice.
Blood.
1997;90:85-96
13.
van der Loo JC, Hanenberg H, Cooper RJ, Luo FY, Lazaridis EN, Williams DA.
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells.
Blood.
1998;92:2556-2570
14.
Enechea G, Segovia JC, Albella B, et al.
Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells.
Blood.
1999;93:1097-1105 15. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis. 1995;172:974-982[Medline] [Order article via Infotrieve]. 16. Christianson SW, Greiner DL, Hesselton RA, et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol. 1997;158:3578-3586[Abstract]. 17. Koyanagi Y, Tanaka Y, Kira J, et al. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain. J Virol. 1997;71:2417-2424[Abstract].
18.
Steele JP, Clutterbuck RD, Powles RL, et al.
Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice.
Blood.
1997;90:2015-2019
19.
Blair A, Hogge DE, Sutherland HJ.
Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR.
Blood.
1998;92:4325-4335
20.
Moore JM, Kumar N, Shultz LD, Rajan TV.
Maintenance of the human malarial parasite, Plasmodium falciparum, in scid mice and transmission of gametocytes to mosquitoes.
J Exp Med.
1995;181:2265-2270 21. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673-680. 22. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1-110[Medline] [Order article via Infotrieve]. 23. Bazin R, Boucher G, Monier G, et al. Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies. J. Immunol. Method. 1994;172:209-217[CrossRef][Medline] [Order article via Infotrieve].
24.
Boucher G, Broly H, Lemieux R.
Restricted use of cationic germline V(H) gene segments in human Rh(D) red cell antibodies.
Blood.
1997;89:3277-3286 25. Khoudi H, Laberge S, Ferullo JM, et al. Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotechnol Bioeng. 1999;64:135-143[CrossRef][Medline] [Order article via Infotrieve]. 26. Issitt PD. Applied Blood Group Serology. Miami: Montgomery Scientific Publications; 1985. 27. Recommended method for radioisotope red-cell survival studies. International Committee for Standardization in Haematology. Br J Haematol. 1980;45:659-666[Medline] [Order article via Infotrieve]. 28. Fahey JL, Sell S. The immunoglobulins of mice. V. The metabolic (catabolic) properties of 5 immunoglobulin classes. J Exp Med. 1965;122:41-48[Abstract].
29.
Kumpel BM, Goodrick MJ, Pamphilon DH, et al.
Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D-volunteers.
Blood.
1995;86:1701-1709 30. Gavin AL, Leiter EH, Hogarth PM. Mouse FcgammaRI: identification and functional characterization of 5 new alleles. Immunogenetics. 2000;51:206-211[CrossRef][Medline] [Order article via Infotrieve]. 31. Luan JJ, Monteiro RC, Sautes C, et al. Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum. J Immunol. 1996;157:4707-4716[Abstract]. 32. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991;9:457-492[Medline] [Order article via Infotrieve]. 33. Thomson A, Contreras M, Gorick B, et al. Clearance of Rh D-positive red cells with monoclonal anti-D. Lancet. 1990;336:1147-1150[CrossRef][Medline] [Order article via Infotrieve]. 34. Blancher A, Socha WW, Roubinet F, et al. Human monoclonal anti-D-induced clearance of human D-positive red cells in a chimpanzee model. Vox Sang. 1993;65:47-54[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Lamoureux, E. Aubin, and R. Lemieux Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg? Int. Immunol., July 1, 2004; 16(7): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
receptors (Fc
) or without (
) 10 mg human IgGs 18 hours before injection of a volume of 100 µL
containing 5 µL 51Cr-labeled Rh D+ RBCs and
35 µL unlabeled Rh D
) or 5 µg
F(ab')2 fragments of polyclonal anti-D (
). RBCs were prepared and
injected as in Figure 
); (B) 5µg 19A5 (
a paradox awaiting resolution?
Trends Immunol.
2001;22:26-30